-+ 0.00%
-+ 0.00%
-+ 0.00%
SynAct Pharma draws SEK 50 million second tranche under Fenja Capital financing facility
Share
Listen to the news
SynAct Pharma draws SEK 50 million second tranche under Fenja Capital financing facility
  • SynAct Pharma draws the SEK 50 million second tranche from Fenja Capital II, fully utilizing its SEK 100 million financing facility.
  • The drawdown is funded through a directed issue of convertibles with a conversion price of SEK 24.60 per share.
  • Borrowings carry annual interest of STIBOR 3M, subject to a 2% floor, plus 8%; repayment falls due December 31, 2027.
  • Conversion of the new convertibles could create 2,032,520 shares, representing 3.49% dilution; full conversion under the facility implies approximately 6.74% dilution.
  • Proceeds will support continued clinical development and strategic priorities.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SynAct Pharma AB published the original content used to generate this news brief on November 18, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending